Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Every cell requires thyroid hormone to function adequately
These criteria reflect clinical evidence showing that GLP-1 therapy works best in people with metabolic risk factors rather than as a general weight-loss tool
Evidence Quality Summary Honest appraisal of the evidence hierarchy for this stack: | Claim | Evidence Level | |---|---| | Ipamorelin raises GH via GHSR-1a | Strong: mechanistic + animal + human Phase I | | CJC-1295 raises GH and IGF-1 in humans | Moderate: Phase II RCT (N=65) | | Combination produces synergistic GH pulses | Moderate in animals
For someone who has obesity, type 2 diabetes, or cardiovascular risk factors, a prescription GLP-1 medication could meaningfully reduce their health risks
Monitoring mental health during the transition to GLP-1 therapy is essential, and any significant mood changes should prompt immediate discussion with a healthcare provider
2025 [cited 2026 Feb 23]
